366 related articles for article (PubMed ID: 25307878)
21. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
22. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
23. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
24. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
26. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
27. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
28. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
30. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
31. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
33. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
35. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
36. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract][Full Text] [Related]
37. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
38. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
[TBL] [Abstract][Full Text] [Related]
39. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
[TBL] [Abstract][Full Text] [Related]
40. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]